Lupin signs deal with China's SUP for Tiotropium DPI rollout

• Lupin signs agreement with Sino Universal Pharmaceuticals to commercialize Tiotropium DPI in China
• SUP to seek regulatory approvals; Lupin to handle manufacturing and hold marketing rights
• Partnership strengthens Lupin's global respiratory health leadership

Pharmaceutical company Lupin Ltd announced that it has entered into a licensing and supply agreement with China's Sino Universal Pharmaceuticals (SUP) for marketing Tiotropium dry powder inhaler (DPI) in China.

Also Read: How to Bridge the Healthcare Gap in Emerging Markets with MedTech

The Tiotropium DPI is indicated for chronic obstructive pulmonary disease (COPD), a significant respiratory illness in patients. The Tiotropium DPI strengths consist of 18 mcg per caps. According to the licensing agreement, SUP will be responsible for regulatory approvals in China while Lupin will retain marketing authorisation and responsible for manufacturing the Tiotropium DPI. The present collaboration aims to increase patient access to leading respiratory therapies in one of the world’s largest healthcare markets.

"This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector," Lupin President Corporate Development, Fabrice Egros said.

Commenting on the partnership, SUP President Wang Li said, "Lupin's deep commitment to respiratory disease treatment and its innovation-driven approach to high-quality products align perfectly with SUP's strategic vision. We believe this collaboration will strengthen our synergy in respiratory care."